FierceBiotech |
Buoyed by new eczema data, AnaptysBio hits the fundraising button
FierceBiotech After a single dose of ANB020, 75% of the 12 enrolled patients achieved an Eczema Area Severity Index score improvement of 50% (EASI-50) or more at day 15, 83% of patients at day 29 and 75% of patients achieved EASI-50 after 57 days or around two … This Biotech Hit Record High; Could Undercut Regeneron In Eczema AnaptysBio Inc. (ANAB) Announces Positive Topline Proof-of-Concept Data from Phase 2A Clinical Trial of ANB020 |
